Published on 21/12/2025
Post-Marketing Surveillance in the United Kingdom: A Regulatory and Operational Guide
Post-marketing surveillance (PMS) trials, often referred to as Phase 4 studies, are critical for monitoring the long-term safety, effectiveness, and real-world use of medicinal products once they have received marketing authorisation. In the United Kingdom (UK), PMS trials form a central pillar of the Medicines and Healthcare products Regulatory Agency (MHRA) pharmacovigilance framework, ensuring that medicines continue to meet safety and efficacy standards under routine healthcare conditions. These trials are essential not only for identifying rare or delayed adverse events but also for informing risk management plans, guiding clinical practice, and shaping reimbursement decisions by health authorities such as the National Institute for Health and Care Excellence (NICE).
This article provides a comprehensive exploration of post-marketing surveillance in the UK, examining the regulatory framework, trial designs, implementation challenges, and best practices for sponsors, CROs, and NHS Trusts. It also discusses how PMS studies interact with pharmacovigilance obligations, real-world evidence generation, and global harmonisation requirements.
Background and Regulatory Framework
Legal Basis
PMS trials in the UK are governed by the Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended) and MHRA guidance on pharmacovigilance. They are aligned
Role of MHRA
MHRA requires post-authorisation safety studies (PASS) and efficacy studies (PAES) under specific conditions, particularly when additional evidence is needed to confirm safety signals or assess long-term effectiveness. Sponsors must integrate these requirements into their Risk Management Plans (RMPs) and maintain compliance with pharmacovigilance reporting standards.
Ethics Oversight
The Health Research Authority (HRA) and Research Ethics Committees (RECs) review PMS protocols to ensure ethical compliance, particularly for observational studies using patient registries or real-world data sources.
Types of Post-Marketing Surveillance Trials in the UK
1. Post-Authorisation Safety Studies (PASS)
These studies are designed to detect, characterise, or quantify safety hazards. They may be imposed by MHRA or conducted voluntarily by sponsors. PASS often involve long-term observational studies, patient registries, or targeted safety monitoring.
2. Post-Authorisation Efficacy Studies (PAES)
MHRA may require PAES to verify clinical benefit in specific populations or subgroups, especially when conditional approvals are granted based on surrogate endpoints.
3. Real-World Evidence (RWE) Studies
NHS datasets, electronic health records (EHRs), and disease registries are increasingly used to conduct pragmatic trials and generate RWE to support regulatory and reimbursement decisions.
4. Registry-Based Studies
UK patient registries provide valuable infrastructure for long-term follow-up. For example, oncology registries and rare disease registries support PMS evidence collection.
5. Observational and Non-Interventional Studies
These include cohort studies, case-control studies, and surveys that examine real-world use of authorised medicines without additional intervention beyond routine care.
Operational Challenges in the UK
NHS Capacity
NHS Trusts often face workforce shortages, making long-term follow-up and data collection challenging. Sponsors must provide adequate funding and training for research staff.
Data Quality and Standardisation
Integration of diverse EHR systems across NHS Trusts introduces variability. Sponsors must implement data validation and harmonisation strategies.
Patient Recruitment and Retention
PMS trials often struggle with patient retention over long follow-up periods. Engagement strategies, patient education, and digital follow-up tools can help.
Pharmacovigilance Integration
Sponsors must ensure seamless integration of PMS trial data into safety databases and global PV reporting systems. This requires validated IT systems and strong CRO oversight.
Best Practices for PMS Trials in the UK
- Align PMS study design with MHRA expectations and NICE evidence needs.
- Engage RECs early to clarify ethical considerations, especially for registry-based studies.
- Implement centralised monitoring and real-time data validation to improve quality.
- Leverage NIHR Clinical Research Network (CRN) support for recruitment and site coordination.
- Maintain a robust pharmacovigilance framework integrated with PMS data flows.
Scientific and Regulatory Evidence
- Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
- MHRA Guidance on Post-Authorisation Safety Studies
- EU GVP Module VIII – Post-Authorisation Safety Studies
- ICH E2E and ICH E2F Guidelines
- NICE Guidance on Real-World Evidence
Special Considerations
- Oncology Trials: PMS trials are critical to monitor long-term safety and survival outcomes in cancer therapies.
- Rare Diseases: Registry-based PMS studies support small populations with limited clinical trial data.
- Pediatrics: Long-term follow-up is essential to monitor developmental impacts of paediatric medicines.
- ATMPs: Advanced therapy medicinal products require extended surveillance, often over decades.
- Decentralised Models: Digital tools enable remote data collection and patient-reported outcomes.
When Sponsors Should Seek Regulatory Advice
- When MHRA imposes PASS or PAES obligations as part of approval.
- For designing registry-based studies in rare diseases.
- When integrating PMS data into global RMPs.
- If inspection findings highlight weaknesses in PMS compliance.
- For novel trial designs using digital endpoints or real-world data.
FAQs
1. What are post-marketing surveillance trials?
They are studies conducted after marketing authorisation to monitor long-term safety, effectiveness, and real-world use of medicines.
2. Who regulates PMS trials in the UK?
MHRA regulates PMS trials, while HRA and RECs oversee ethical aspects of protocols and patient engagement.
3. What is the difference between PASS and PAES?
PASS focus on safety monitoring, while PAES evaluate long-term efficacy or benefit in specific populations.
4. Do PMS trials contribute to pharmacovigilance?
Yes. PMS data are integrated into pharmacovigilance systems and risk management plans to ensure ongoing safety monitoring.
5. Are PMS trials mandatory?
They may be imposed by MHRA as conditions of approval, or sponsors may conduct them voluntarily for evidence generation.
6. How does NICE use PMS data?
NICE relies on PMS evidence to update guidance on cost-effectiveness and reimbursement decisions.
7. Can CROs manage PMS trials in the UK?
Yes. CROs often support PMS trial operations, pharmacovigilance, and data management, but sponsors remain accountable.
8. How are PMS trials affected by Brexit?
UK requirements are now nationally defined, though aligned with EU GVP. Sponsors must ensure compliance with both UK and EU obligations for multinational trials.
Conclusion
Post-marketing surveillance trials in the UK are essential for maintaining medicine safety and public trust beyond the point of authorisation. With MHRA oversight, HRA ethical governance, and NHS infrastructure, PMS studies generate crucial evidence for long-term safety, effectiveness, and real-world application. Sponsors, CROs, and investigators must adopt best practices in trial design, pharmacovigilance integration, and data quality management to meet regulatory expectations. As the UK advances its independent framework post-Brexit, PMS trials will continue to shape both patient safety outcomes and healthcare policy decisions.